Course curriculum

    1. Brian Sworder - Utility of ctDNA in CART and bispecific therapy

    2. Steve Grupp - Tisa-cel in pediatric B-ALL. Current and future plans

    3. Nitin Jain - Brexu-cel in adults B-ALL. Current and future plans

    4. Rebecca Gardner - CD22 CAR-T’s - Promise and Perils

    5. Session 1 Panel Discussion 2

    1. Elias Jabbour - Role of Bispecifics (CD19, CD20) in B-ALL

    2. Anjali Advani - Incorporating CAR-T in current management of Adult ALL

    3. Catherine Coombs - CAR-T in CLL

    4. Session 2 Panel Discussion

    5. Nitin Jain - Case Presentation

    1. David Miklos - David Miklos, MD

    2. Andrew Jallouk Mechanisms Affecting Allogeneic CAR-T Cell Expansion and Rejection

    3. Session 3 Panel Discussion

    1. Maksim Mamonkin - CAR-T for T-cell neoplasms

    2. Amrita Krishnan - Emerging Bispecifics

    3. Noopur Raje Mechanisms of CAR Resistance and novel targets with MM

    4. Session 4 Panel Discussion

    1. Chris Flowers - Value of real-world studies/outcomes research

    2. Matthew Lunning - CD19 CAR-T in LBCL

    3. Elizabeth Budde CD20 Bispecifics in LBCL

    4. Bijal Shah - CD19 CAR-T in MCL

    5. Session 5 Panel Discussion 2

    1. Reem Karmali - CD19 CAR-T in indolent NHL

    2. Krish Patel - CD20 Bispecifics in MCL and NHL

    3. Justin Kline - Bispecifics vs CAR-T in NHL

    4. Session 6 Panel Discussion

    5. Sattva Neelapu - Case Presentation

About this course

  • Free
  • 38 lessons
  • 14 hours of video content

Video